News and Trends 26 Sep 2016 Terrible Turing hasn’t given up on Toxoplasmosis (or its Karma) The biopharmaceutical company’s Swiss division just published computational studies aiming to improve Daraprim, after its former CEO, Martin Shkreli, attempted to justify the scandalous 5000% price hike as a boost for its R&D. A little over a year ago, Martin Shkreli, founder and then-CEO of Turing Pharmaceuticals, hiked the price of a common medication for toxoplasmosis by […] September 26, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2016 This French Founder is on a mission of Connecting Medical Devices What happens when you mix Internet of Things and Medical Devices? That’s what the French Startup, Instent, and its co-founder, Franz Bozsak, intend to find out. I had a chat with him after he won the EY prize of the Best Parisian Entrepreneur of the Year for his startup. My first question was which language should we speak? Bozsak is […] September 26, 2016 - 3 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 24 Sep 2016 The Future of Portugal as explained by Microorganisms Microbiology makes its mark at the first edition of the London Design Biennale taking place in Somerset House. Portugal’s exhibition by Marta de Menezes uses bacteria and viruses to create changing art that represents the future direction of the country. With the common topic “Design by Utopia“, 30 nations have interpreted utopic and dystopic futures using art to […] September 24, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 23 Sep 2016 SELLAS wants to sell us an Immunotherapy for Mesothelioma After Cyprus, we mosey back to the mainland to visit the country gave the world the cuckoo clock. That’s right, we’re Schweiz-bound. In Switzerland, we’ll meet an immuno-oncology biotech, SELLAS Life Sciences. City: Zug (Zurich-area), Switzerland Founded: 2012 Employees: 11 – 50 Financial Data: None available…what a secretive cohort. Mission: SELLAS Life Sciences is a development-stage biopharmaceutical company focused on […] September 23, 2016 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 23 Sep 2016 The Munich Biotech Mafia are at it again, raising €40M for an I/O Startup A new immuno-oncology startup has taken off with a booming round of VC fundraising. Details on its programs are sparse, but the company’s leadership is a veritable who’s who in German biotech, much like the PayPal Mafia. Immuno-oncology is surely an exciting field, but high-profile leadership is a huge bonus when it comes to attracting […] September 23, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2016 Evotec and Bayer renew their vows and take on Kidney Disease Evotec and Bayer are approaching the 4th anniversary of a successful partnership in endometriosis treatments that made it to clinical trials just last month. To celebrate, they’re starting a new 5-year partnership, this time concerning kidney disease. Evotec has a long list of top-level partners, including Roche, Sanofi, Boehringer Ingelheim and Takeda. After the successful outcome of […] September 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2016 After only 6 months, Akarna seals the deal with Allergan for €44.8M upfront Earlier this week, we announced the launch of a new diagnostic tool for NASH by the French company Genfit. Now, Ireland strikes back with the acquisition of Akarna with a €44.8M upfront payment. Akarna focuses on the development of drugs for Non-Alcoholic Steato-Hepatitis (NASH) and boasts to count with a potentially best-in-class therapeutic candidate still in preclinical trials. The […] September 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2016 A new player has entered the Game: €29M for DDR Cancer Therapy Artios Pharma, launched in May this year, just received €29M (£25M) in Series A to develop cancer treatments. Its technology targets the DNA-Damage Response (DDR) and could overcome one of the main challenges of cancer therapy. Top-notch investors from Europe and the US have eagerly thrown cash at Artios Pharma in their search for new cancer treatments. […] September 21, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2016 German Biotech allies with Genentech in battle for Cancer Vaccine BioNTech has turned up the heat in the race to bring an mRNA immunotherapy for cancer to the clinic. The German biotech has partnered with American giant Genentech in a massive deal with almost €300M upfront. Europe’s largest private biotech, BioNTech, has partnered up with Genentech to produce individualized mRNA-based cancer therapies. The collaboration aims […] September 21, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 20 Sep 2016 This company just turned the lights ON for NanoMed Bioplastic Bio-ON just patented the first application of bioplastic in nanomedicine with a diagnostic tool for cancer that will grant it access to a whole new market previously inaccessible to this industry. Italy-based Bio-ON is trying to change the world by producing alternative sustainable chemicals and bioplastic materials with industrial applications. Their newest product, minerv BIOMEDS, will be used […] September 20, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Sep 2016 UPDATE: Novartis is Favoured to Win the Race for a New MS Drug Novartis is poised to kick off the next generation of multiple sclerosis treatments after siponimod performs well in Phase III. The company’s primary competitor had been Biogen, but its drug’s failure in Phase II leaves siponimod the last man standing. Novartis reports that its multiple sclerosis (MS) drug, siponimod, has reached its primary endpoint in Phase III […] September 20, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 20 Sep 2016 Genfit’s Non-Invasive Diagnostic could unlock the NASH Market Genfit reinforced its leading place in the race to find a cure for NASH when it announced this morning the launch of a program to validate their new diagnostic tool. Genfit is already leading in the development of a cure for Non-Alcoholic Stato-Hepatitis (NASH) with its candidate, Elafibranor, which is in Phase III trials. Now, the French €600M biopharma has […] September 20, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email